Hemab Therapeutics Holdings

Update in progress

COAG (NasdaqGS)

Hemab Therapeutics Holdings, Inc. is a clinical‑stage biotechnology company focused on therapies for blood coagulation disorders to extend and protect life. Based in Cambridge, Massachusetts, with activities in the United States and Denmark, it develops HMB‑001, a bispecific antibody in Phase 1/2 for prophylaxis of Glanzmann thrombasthenia and Factor VII deficiency; HMB‑002, a monovalent antibody in Phase 1/2 for subcutaneous prophylaxis of Von Willebrand disease, plus multiple preclinical programs.